Keywords: Merck KGaA, Meck Serono, Cladribine, Movectro, Multiple Sclerosis, USA, FDA, Safety data

Another blow for Merck KGaA as US FDA calls for more safety data on cladribine in MS

Article | 02 March 2011

Print This

In a further setback for German drug major Merck KGaA (MRK: DE) in its aim to bring an oral multiple ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in